216 related articles for article (PubMed ID: 35752431)
1. Adherence and Persistence to Single-Inhaler Versus Multiple-Inhaler Triple Therapy for Asthma Management.
Busse WW; Abbott CB; Germain G; Laliberté F; MacKnight SD; Jung Y; Duh MS; Averell CM
J Allergy Clin Immunol Pract; 2022 Nov; 10(11):2904-2913.e6. PubMed ID: 35752431
[TBL] [Abstract][Full Text] [Related]
2. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study.
Mannino D; Bogart M; Wu B; Germain G; Laliberté F; MacKnight SD; Jung Y; Stiegler M; Duh MS
Respir Med; 2022 Jun; 197():106807. PubMed ID: 35429764
[TBL] [Abstract][Full Text] [Related]
3. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
Bogart M; Bengtson LGS; Johnson MG; Bunner SH; Gronroos NN; DiRocco KK
Int J Chron Obstruct Pulmon Dis; 2024; 19():97-110. PubMed ID: 38226396
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
Beeh KM; Rothnie KJ; Claussen J; Hardtstock F; Knapp RK; Wilke T; Czira A; Compton C; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2024; 19():945-956. PubMed ID: 38646606
[TBL] [Abstract][Full Text] [Related]
5. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
Mannino D; Bogart M; Germain G; Huang SP; Ismaila AS; Laliberté F; Jung Y; MacKnight SD; Stiegler MA; Duh MS
Int J Chron Obstruct Pulmon Dis; 2022; 17():491-504. PubMed ID: 35281476
[TBL] [Abstract][Full Text] [Related]
6. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
[TBL] [Abstract][Full Text] [Related]
8. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
Nakamura Y; Hozawa S; Sagara H; Ohbayashi H; Lee LA; Crawford J; Tamaoki J; Nishi T; Fowler A
Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
[TBL] [Abstract][Full Text] [Related]
12. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Day NC; Kumar S; Criner G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kaisermann MC; Kilbride S; Lange P; Lomas DA; Martin N; Martinez FJ; Singh D; Wise R; Lipson DA
Respir Res; 2020 Jun; 21(1):139. PubMed ID: 32503599
[TBL] [Abstract][Full Text] [Related]
13. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
Bardsley S; Criner GJ; Halpin DMG; Han MK; Hanania NA; Hill D; Lange P; Lipson DA; Martinez FJ; Midwinter D; Siler TM; Singh D; Wise RA; van Zyl-Smit RN; Berkman N
Respir Med; 2022 Dec; 205():107040. PubMed ID: 36470149
[TBL] [Abstract][Full Text] [Related]
14. Real-world characteristics of patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy in Japan.
Oga T; Mita C; Ito R; Requena G; Rothnie KJ; Noorduyn SG; Yuanita L; Yarita M
Respir Investig; 2024 May; 62(4):685-694. PubMed ID: 38796907
[TBL] [Abstract][Full Text] [Related]
15. Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial.
Zheng J; Zhong N; Wang C; Wei LP; Zhou XD; Zhao L; Dong Yuan Y; He B; Wu B; Du X; Song J; Lipson DA
Curr Med Res Opin; 2021 Jan; 37(1):145-155. PubMed ID: 33124900
[TBL] [Abstract][Full Text] [Related]
16. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
[TBL] [Abstract][Full Text] [Related]
17. Real-world users of triple therapy for asthma in the US.
Hansel NN; Abbott CB; Averell CM; Germain G; Laliberté F; Mahendran M; Duh MS; Settipane RA
Am J Manag Care; 2024 Feb; 30(2):74-81. PubMed ID: 38381542
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
Moretz C; Bengtson LG; Sharpsten L; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
Yang S; Lee LA; Sule N; Fowler A; Peachey G
Clin Pharmacokinet; 2021 Jul; 60(7):887-896. PubMed ID: 33598874
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study.
Rothnie KJ; Wood RP; Czira A; Banks VL; Camidge LJ; Massey OKI; Seif M; Compton C; Sharma R; Halpin DMG; Ismaila AS; Vogelmeier CF
BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38772900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
